NIH Reporter #1R01AI194953-01

NIAID Grant for Immunomodulatory Research in AAV Gene Therapy at Duke University

This opportunity is a research grant solicitation from the National Institute of Allergy and Infectious Diseases (NIAID) focused on immunomodulation in AAV gene therapy at Duke University. - Government Buyer: - National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) - Project to be conducted at Duke University's Department of Surgery - Products/Services Requested: - Research and development of immunomodulatory agents (e.g., IceMG, IceRx) to improve safety and efficacy of adeno-associated virus (AAV) gene therapy - No specific products, part numbers, or purchase quantities are listed - OEMs and Vendors: - No specific Original Equipment Manufacturers (OEMs) or commercial vendors are named in the solicitation - Unique or Notable Requirements: - Focus on engineering and testing new immunomodulatory regimens for gene therapy - Multiyear research project with significant funding - Standard NIH grant application process applies - No unique licensing, classification, or procurement vehicle requirements specified

Description

This NIH grant opportunity supports research on developing immunomodulatory regimens for AAV gene therapy. The focus is on engineering agents such as IceMG and IceRx to mitigate immune responses and improve safety and efficacy in gene therapy applications. The project is a multiyear award with a total estimated cost of $3,192,404. The grant is open for applications and follows the standard NIH application process.

View original listing